The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
Open accessAbstract
Purpose: Interleukin-15 (IL-15) has significant potential in cancer immunotherapy as an activator of antitumor CD8 T and natural killer (NK) cells. The primary objectives of this trial were to determine safety, adverse event profile, dose-limiting toxicity, and maximum-tolerated dose of recombinant human IL-15 (rhIL-15) administered as a daily intravenous bolus infusion for 12 consecutive days in patients with metastatic malignancy. Patients and Methods: We performed a first in-human trial of Escherichia coli–produced rhIL-15. Bolus infusions of 3.0, 1.0, and 0.3 μg/kg per day of IL-15 were administered for 12 consecutive days to patients with metastatic malignant melanoma or metastatic renal cell cancer. Results: Flow cytometry of peripheral blood lymphocytes revealed dramatic efflux of NK and memory CD8 T cells from the circulating blood within minutes of IL-15 administration, followed by influx and hyperproliferation yielding 10-fold expansions of NK cells that ultimately returned to baseline. Up to 50-fold increases of serum levels of multiple inflammatory cytokines were observed. Dose-limiting toxicities observed in patients receiving 3.0 and 1.0 μg/kg per day were grade 3 hypotension, thrombocytopenia, and elevations of ALT and AST, resulting in 0.3 μg/kg per day being determined the maximum-tolerated dose. Indications of activity included clearance of lung lesions in two patients. Conclusion: IL-15 could be safely administered to patients with metastatic malignancy. IL-15 administration markedly altered homeostasis of lymphocyte subsets in blood, with NK cells and γδ cells most dramatically affected, followed by CD8 memory T cells. To reduce toxicity and increase efficacy, alternative dosing strategies have been initiated, including continuous intravenous infusions and subcutaneous IL-15 administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Reversible Defects in Natural Killer and Memory Cd8 T Cell Lineages in Interleukin 15–Deficient Mice
Kennedy, M. K., Glaccum, M., Brown, S. N., Butz, E. A., Viney, J. L., Embers, M., Matsuki, N., Charrier, K., Sedger, L., Willis, C. R., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.5.771 · Cited by 1,634
Cloning of a T Cell Growth Factor that Interacts with the β Chain of the Interleukin-2 Receptor
Grabstein, K. H., Eisenman, J., Shanebeck, K., Rauch, C., Srinivasan, S., Fung, V., Beers, C., Richardson, J., Schoenborn, M. A., Ahdieh, M., et al. (1994) · Science · doi:10.1126/science.8178155 · Cited by 1,422
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
Waldmann, T. A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1901 · Cited by 1,178
Self-citationRosenberg, S. A. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510360033032 · Cited by 1,131
Self-citationInterleukin-2 Receptor γ Chain: a Functional Component of the Interleukin-7 Receptor
Noguchi, M., Nakamura, Y., Russell, S. M., Ziegler, S. F., Tsang, M., Cao, X., & Leonard, W. J. (1993) · Science · doi:10.1126/science.8266077 · Cited by 1,109
IL-15Rα Recycles and Presents IL-15 In trans to Neighboring Cells
Dubois, S., Mariner, J., Waldmann, T. A., & Tagaya, Y. (2002) · Immunity · doi:10.1016/s1074-7613(02)00429-6 · Cited by 913
Self-citationSPICE: Exploration and analysis of post‐cytometric complex multivariate datasets
Roederer, M., Nozzi, J. L., & Nason, M. C. (2011) · Cytometry Part A · doi:10.1002/cyto.a.21015 · Cited by 831
Self-citationSynergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function
Zeng, R., Spolski, R., Finkelstein, S. E., Oh, S., Kovanen, P. E., Hinrichs, C. S., Pise-Masison, C. A., Radonovich, M. F., Brady, J. N., Restifo, N. P., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041057 · Cited by 727
Waldmann, T. A., & Tagaya, Y. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.19 · Cited by 721
Self-citationInterleukin 15 Is Required for Proliferative Renewal of Virus-specific Memory CD8 T Cells
Becker, T. C., Wherry, E. J., Boone, D., Murali-Krishna, K., Antia, R., Ma, A., & Ahmed, R. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020369 · Cited by 683
IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients
Ahmadzadeh, M., & Rosenberg, S. A. (2006) · Blood · doi:10.1182/blood-2005-06-2399 · Cited by 632
Self-citationGiri, J. G., Kumaki, S., Ahdieh, M., Friend, D. J., Loomis, A., Shanebeck, K., DuBose, R., Cosman, D., Park, L. S., & Anderson, D. M. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00035.x · Cited by 628
Teachey, D. T., Rheingold, S. R., Maude, S. L., Zugmaier, G., Barrett, D. M., Seif, A. E., Nichols, K. E., Suppa, E. K., Kalos, M., Berg, R. A., et al. (2013) · Blood · doi:10.1182/blood-2013-02-485623 · Cited by 613
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 + T Cells
Klebanoff, C. A., Finkelstein, S. E., Surman, D. R., Lichtman, M. K., Gattinoni, L., Theoret, M. R., Grewal, N., Spiess, P. J., Antony, P. A., Palmer, D. C., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307298101 · Cited by 577
Self-citationWaldmann, T. (2001) · Immunity · doi:10.1016/s1074-7613(09)00091-0 · Cited by 434
Self-citationIL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice
Marks-Konczalik, J., Dubois, S., Losi, J. M., Sabzevari, H., Yamada, N., Feigenbaum, L., Waldmann, T. A., & Tagaya, Y. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.200363097 · Cited by 433
Self-citationBamford, R. N., Grant, A. J., Burton, J. D., Peters, C., Kurys, G., Goldman, C. K., Brennan, J., Roessler, E., & Waldmann, T. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4940 · Cited by 411
Self-citationSugamura, K., Asao, H., Kondo, M., Tanaka, N., Ishii, N., Ohbo, K., Nakamura, M., & Takeshita, T. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.179 · Cited by 407
Burton, J. D., Bamford, R. N., Peters, C., Grant, A. J., Kurys, G., Goldman, C. K., Brennan, J., Roessler, E., & Waldmann, T. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4935 · Cited by 397
Self-citationBurkett, P. R., Koka, R., Chien, M., Chai, S., Boone, D. L., & Ma, A. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041389 · Cited by 392
Cesana, G. C., DeRaffele, G., Cohen, S., Moroziewicz, D., Mitcham, J., Stoutenburg, J., Cheung, K., Hesdorffer, C., Kim-Schulze, S., & Kaufman, H. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6830 · Cited by 349
Interleukin-2 and interleukin-15: immunotherapy for cancer
Fehniger, T. A., Cooper, M. A., & Caligiuri, M. A. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00021-1 · Cited by 280
Kobayashi, H., Dubois, S., Sato, N., Sabzevari, H., Sakai, Y., Waldmann, T. A., & Tagaya, Y. (2005) · Blood · doi:10.1182/blood-2003-12-4187 · Cited by 275
Self-citationIL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients
Sim, G. C., Martin-Orozco, N., Jin, L., Yang, Y., Wu, S., Washington, E., Sanders, D., Lacey, C., Wang, Y., Vence, L., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci46266 · Cited by 229
Munger, W., Dejoy, S. Q., Jeyaseelan, R., Torley, L. W., Grabstein, K. H., Eisenmann, J., Paxton, R., Cox, T., Wick, M. M., & Kerwar, S. S. (1995) · Cellular Immunology · doi:10.1006/cimm.1995.1216 · Cited by 200
Waldmann, T. A., Lugli, E., Roederer, M., Perera, L. P., Smedley, J. V., Macallister, R. P., Goldman, C. K., Bryant, B. R., Decker, J. M., Fleisher, T. A., et al. (2011) · Blood · doi:10.1182/blood-2010-10-311456 · Cited by 195
Self-citationFas and the art of lymphocyte maintenance.
Lenardo, M. J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.721 · Cited by 192
Sandau, M. M., Schluns, K. S., Lefrancois, L., & Jameson, S. C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.11.6537 · Cited by 175
Wei, S., Kryczek, I., Edwards, R. P., Zou, L., Szeliga, W., Banerjee, M., Cost, M., Cheng, P., Chang, A., Redman, B., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0565 · Cited by 159
Fueling regulation: IL-2 keeps CD4+ Treg cells fit
Maloy, K. J., & Powrie, F. M. (2005) · Nature Immunology · doi:10.1038/ni1105-1071 · Cited by 137
Development and proliferation of lymphocytes in mice deficient for both interleukins‐2 and ‐4
Sadlack, B., Kühn, R., Schorle, H., Rajewsky, K., Müller, W., & Horak, I. D. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240144 · Cited by 136
Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates
Lugli, E., Goldman, C. K., Perera, L. P., Smedley, J. V., Pung, R., Yovandich, J. L., Creekmore, S. P., Waldmann, T. A., & Roederer, M. (2010) · Blood · doi:10.1182/blood-2010-03-275438 · Cited by 127
Self-citationYu, P., Steel, J. C., Zhang, M., Morris, J. C., Waitz, R., Fassò, M., Allison, J. P., & Waldmann, T. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203479109 · Cited by 126
Self-citationInterleukin-6 in Sepsis and Capillary Leakage Syndrome
Krüttgen, A., & Rose‐John, S. (2011) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2011.0062 · Cited by 120
Evans, R., Fuller, J. A., Christianson, G. J., Krupke, D. M., & Troutt, A. B. (1997) · Cellular Immunology · doi:10.1006/cimm.1997.1132 · Cited by 102
Sneller, M. C., Kopp, W. C., Engelke, K. J., Yovandich, J. L., Creekmore, S. P., Waldmann, T. A., & Lane, H. C. (2011) · Blood · doi:10.1182/blood-2011-09-377804 · Cited by 100
Self-citationZhang, M., Ju, W., Yao, Z., Yu, P., Wei, B., Simpson, R. J., Waitz, R., Fassò, M., Allison, J. P., & Waldmann, T. A. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102604 · Cited by 49
Self-citationKudo‐Saito, C., Wansley, E. K., Gruys, M. E., Wiltrout, R. H., Schlom, J., & Hodge, J. W. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2398 · Cited by 23
Cited by
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
The immunopathology of sepsis and potential therapeutic targets
van der Poll, T., van de Veerdonk, F. L., Scicluna, B. P., & Netea, M. G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.36 · Cited by 1,957
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
NK cells for cancer immunotherapy
Shimasaki, N., Jain, A., & Campana, D. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0052-1 · Cited by 1,222
Metadata
- Authors
- Conlon, K. C., Lugli, E., Welles, H. C., Rosenberg, S. A., Fojo, A. T., Morris, J. C., Fleisher, T. A., Dubois, S. P., Perera, L. P., Stewart, D. M., Goldman, C. K., Bryant, B. R., Decker, J. M., Chen, J., Worthy, T. A., Figg, W. D., Peer, C. J., Sneller, M. C., Lane, H. C., Yovandich, J. L., Creekmore, S. P., Roederer, M., & Waldmann, T. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-01-01
- Volume
- 33
- Issue
- 1
- Pages
- 74-82
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2120072658
- Cited by
- 711
- References
- 40
- FWCI
- 17.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.